UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
NEW YORK, March 28, 2017 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”), a corporation headquartered in Cambridge, Massachusetts and incorporated in Delaware, and certain of its senior officers and executives. If you purchased Sarepta stock between October 1, 2015 and January 15, 2016, you are encouraged to contact a Scott+Scott attorney toll free at (844) 818-6980 for more information.
Sarepta is a biopharmaceutical company focused on the discovery and development of therapeutics for the treatment of rare, infectious and other diseases. The Company developed the drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease. Eteplirsen is designed to increase the underlying cause of DMD by enabling production of the protein dystrophin.
In October 2015, Sarepta told the public, including investors, that clinical trials of eteplirsen had demonstrated “dystrophin production in nearly all patients,” “dystrophin intensity that was statistically significant,” and “dystrophin production [that] was in fact robust.”
On January 15, 2016, the U.S. Food and Drug Administration (“FDA”) released an analysis of Sarepta’s eteplirsen trials. Among other things, the FDA pointed out that DMD experts had stated that “induction of approximately 10% of normal dystrophin levels sets a minimum level to confer measurable clinic benefit.” Dystrophin levels after Sarepta’s eteplirsen treatment were only reported to be about 0.9% of normal. Thus, the FDA report disclosed that eteplirsen had not shown the “significant” increase in dystrophin that Sarepta had touted.
On this news, the price of Sarepta common stock plummeted more than 54%, from $31.63 on January 14, 2016 to close at $14.28 on January 15, 2016.
What You Can Do
If you purchased Sarepta stock between October 1, 2015 and January 15, 2016 and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.
CONTACT: Rhiana Swartz Scott+Scott, Attorneys at Law, LLP (844) 818-6980 [email protected]
